Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022 05 05; 139(18):2797-2815.
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
-
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).
-
Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks. Best Pract Res Clin Haematol. 2019 03; 32(1):47-53.
-
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol. 2014 Mar 19; 7:25.
-
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
-
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol. 2011 Oct 10; 4:40.
-
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
-
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008 May 15; 111(10):5109-17.
-
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark. 2007; 3(6):315-24.